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Abstract
FGF23 is a novel phosphaturic hormone; we aimed to assess the FGF23 levels and its association with dietary 
phosphate intake and indices of renal handling of phosphate in this study. Prospective study was conducted in which 
dietary phosphate intake was assessed by food frequency questionnaire (FFQ) along with blood and spot urine samples 
were collected after overnight fast for determining serum phosphate, FGF23, fractional excretion of phosphate (FePO4) 
and tubular maximum for phosphate (TmP/GFR). FGF23 (C-Term) was measured by a sandwich ELISA. 
The mean dietary phosphate intake of eighty healthy adults (mean age of 29 ± 5 years) was 1220 ± 426 mg; median 
FGF23 was 49.9 RU/ml (IQR=33, 76) and mean FePO4 was 7 ± 4.7. Subjects were stratified into two groups according 
to serum phosphate levels. Significant difference was not found in dietary phosphate intake and FGF23 levels in the 
two groups. However, TmP/GFR and creatinine were significantly different in the two groups. FePO4 was high in both 
the groups. 
Overall a rising pattern of FGF23 levels was seen with increasing serum phosphate levels. Significant positive 
correlation was found between FGF23 and dietary phosphate (r=0.22, p<0.05) and negative correlation was seen 
between FGF23 and FePO4 (r=-0.260, p<0.05).
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Introduction
Fibroblast 23 (FGF23) is primarily expressed in osteocytes and 
in endothelial cells lining the venous sinusoids of bone marrow and 
thymus [1]. Most of its functions occur in the kidney through an FGF 
receptor (FGFR)/Klotho complex; and it acts opposite to vitamin D 
by inhibiting 1 alpha hydroxylase and stimulating 24 hydroxylase 
enzymes in the renal tubule. As a result, 1,25 OH vitamin D catabolism 
is increased with decrease in production due to excess of FGF23 [2]. 
Moreover, the expression of type II sodium-dependent phosphate co-
transporters (mainly NPT2a and NPT2c) is inhibited by FGF23 in cells 
of renal proximal tubules which reduces phosphate reabsorption and 
consequently increases urinary phosphate excretion.
FGF 23 also interacts negatively with PTH mRNA in contrast 
to CKD, where increased FGF23 is associated with secondary 
hyperparathyroidism. Due to these opposing verdicts; local and 
systemic confounding factors have been projected to modify FGF23 
levels and taken together, it is advocated that PTH and FGF23 axis is 
similar to vitamin D-FGF23 loop [2].
Another main stimulus for FGF23 released is increased phosphate 
intake as evinced by the literature, as FGF23 levels were not increased 
by the rise in serum phosphate levels due to non-dietary interventions 
[3]. Literature showed that consumption of diet low in calcium and 
high in phosphorus have detrimental effects on the normal physiology 
of peak bone mass which leads to osteoporosis in later life. Both short 
term and longer consumption of phosphate causes increase in PTH 
levels and thus increases bone turnover. On the other hand despite 
minor rise in PTH levels, calcitriol showed a significant reduction or 
no change in concentrations.
As FGF23 is a novel regulator of phosphate homeostasis and its 
has actions on PTH and 1,25 (OH)2 D metabolism and is considered 
key factor in bone cellular, metabolic, and mineralization functions. 
Hence, both over and under expression of FGF23 results in negatively 
affecting bone mineralization; while its deficiency leading to severe 
hypophosphatemia, hyper vitaminosis D, and increased circulating 
calcium [2]. The extra renal functions of FGF23 are important apart 
from renal failure, as the association of FGF23 with adversative 
outcomes including cardiovascular changes is sturdier. 
Studies showed that higher FGF23 levels are now associated 
with cardiovascular complications and death. Association of FGF23 
concentrations with adversarial outcomes is stronger in patients with 
CKD as it is not captured by measurement of routine biomarkers for 
CKD i.e., eGFR or albuminuria [3].
FGF23 has not been studied in our population. We presumed that 
FGF23 is high in our subjects due to high dietary phosphate intake [4]. 
This has implications for the bone health and diagnosis and treatment 
of phosphate-wasting disorders and vitamin D metabolic defects. The 
purpose of this study was to explore FGF23 levels in healthy subjects 
and assess its relationship with serum phosphate; TmP/GFR, FePO4 
and dietary phosphate. 
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Materials and Methods
A prospective cross sectional study took place at Section of Clinical 
Chemistry, Department of Pathology and Laboratory Medicine, Aga 
Khan University, Karachi. The study was reviewed and accepted by the 
Ethical Review Committee, Aga Khan University Hospital. 
Healthy subjects of either gender staff were recruited after informed 
consent. A performa including the demographics age, gender, ethnicity, 
occupation was filled at the time of drawing blood.
Blood sample was taken from study subjects after an overnight 
fast, in ethylene diamine tetra acetic acid (EDTA) and gel tubes for 
analysis of FGF23 and serum phosphate and creatinine respectively. 
At the same time subjects were asked to provide a spot urine sample 
for phosphate and creatinine measurements. Plasma was collected after 
centrifugation at 3000 rpm for 5 min. Aliquotting of plasma samples 
was performed, and tubes were labeled and kept at -70°C till analysis of 
plasma FGF23, serum creatinine and phosphate. 
Dietary information was recorded on food frequency questionnaires 
(FFQ) through a face-to-face interview with the principal investigator, 
and the duration of each interview took about 20 to 25 minutes. The 
FFQ was previously validated [5]. The raw composition of phosphate 
content in each food item was taken from the U.S. Department 
of Agriculture, Agricultural Research Service, and Nutrient data 
laboratory. In certain cases where this information was not available 
from the USDA, other local food composition tables were consulted 
[6]. Dietary data for phosphate content were totaled by multiplying the 
intake frequency of each food item by the phosphate content of the 
given portion sizes.
FGF23 levels (C-term) were measured by a sandwich enzyme 
linked immunosorbent assay (ELISA) from Immunotopics Inc. (San 
Clemente, California). Both normal and abnormal control materials 
were run to assure quality of analysis. The normal reference range for 
plasma FGF23 was taken as median 52.4 RU/ml [4,7,8].
Plasma and urinary phosphate and creatinine levels were measured 
by Synchron CX9 by Beckmann instruments Brea, California USA 
based on spectrophotometric principle. To ensure quality, two levels of 
controls (normal and abnormal) were run with each batch of plasma, 
serum and urinary phosphate and creatinine analysis. The laboratory 
participated in external proficiency testing from BIORAD laboratories 
California, USA for phosphate and creatinine every three months.
Values for serum phosphate, serum creatinine, urinary phosphate 
and creatinine were utilized for derivation of FePO4 and TmP/GFR by 
using these formulae [9]:
( )
( ) ( )
PO4 PO4 cr cr
4 PO4 cr PO4 cr
TmP / GFR  S –  U S /  U
FePO  U S  /  S U   100%
= ×
= × × ×
Normal range for TmP/GFR was 2.4-4.8 mg/dl and cutoff for 
normal FePO4 was taken as <5%.
SPSS version 19 was used to compute and analyze the data. 
Frequencies of gender were generated. Means and standard deviations 
for continuous variables (age, serum FGF23, serum and urinary 
phosphate and serum and urinary creatinine) and proportion for 
categorical variables (gender, ethnic origin, and education) was also 
computed. A confidence interval of 95%, for the FGF23 was reported. 
Data of FGF23 was skewed so median value was reported along with 
interquartile ranges. We had also compared two groups of serum 
phosphate using Mann-Whitney U Test and association between 
log transformed FGF23, serum phosphate, dietary phosphate, serum 
creatinine, FePO4 and TmP/GFR using spearman’s correlation 
coefficient.
Effect modifiers were controlled through age, gender, serum 
phosphate; dietary phosphate, FePO4, serum creatinine and TmP/
GFR to see the impact on the outcome variable. A p-value of <0.05 was 
considered as significant and p value<0.01 as highly significant in all 
statistical analysis.
Results
Eighty subjects were recruited in the study. The mean age of the 
study subjects was 29 ± 4.7 years with 51% (n=41) being females. 
Table 1 shows the anthropometric details and biochemical parameters 
assessed in study subjects.
Relation of serum phosphate with FGF23 and indices of renal 
handling 
Only one subject had high serum P (>4.5 mg/dl), with high dietary 
phosphate intake (1685.6 mg) and high FePO4 (8.5%) and FGF23 levels 
of 54.9 RU/ml. This subject was excluded from final analysis. 
Table 2 shows indices of renal handling, dietary phosphate 
intake and FGF23 levels in 79 subjects with low and normal serum 
phosphate levels. Six subjects (11%) were identified to have low mean 
serum phosphate levels (2.3 ± 0.2 mg/dl), the cause of which is not 
known. Mean TmP/GFR was low and FEPO4 was high in subjects with 
hypophosphatemia. FGF23 concentrations were increased in only 2 
subjects, while the rest have levels less than the cut off. 
Creatinine and TmP/GFR were significantly different between 
subjects with low and normal serum phosphate levels. 
Distribution of FGF23 and association with indices of renal 
handling 
Log FGF23 showed a statistically significant negative correlation 
with serum creatinine (p<0.05) and FEPO4 (p<0.05). Significant 
association was not found with serum PO4, dietary phosphate and 
TmP/GFR (Table 3). However, with increase in median FGF23 
quartiles, a downward trend is seen in serum phosphate and TmP/GFR 
and upward trend in FePO4  (Tables 4 and 5). 
Gender
Male                                                                                                                                               
Female
49% (n = 39)
51% (n= 41)
Mean Age
(Yrs.)
29 ± 4.7
Mean BMI
(kg/m2)
22.98 ± 3.91
Mean Serum PO4
(mg/dl)
3.35 ±  3.91
Mean TmP/GFR
(mg/dl)
3.04 ± 0.57
Mean FePO4
(%)
7.0 ± 4.7
Mean Dietary 
Phosphate
(mg)
1220 ± 426
Median FGF-23
(RU/ml)
49.9 (33-76.1)
Abbreviations used: BMI, Body Mass Index; FGF-23, Fibroblast growth factor 23; 
TmP/GFR, Tubular maximum re-absorption of phosphorus per unit of GFR; PO4, 
Phosphate; FePO4, fractional excretion of Phosphate.
Table 1: Demographic, Dietary Phosphate Intake and Biochemical Characteristics 
of Study Subjects (n=80).
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Discussion
FGF23 is a bone-generated major regulator of phosphate 
homeostasis. It is identified in healthy individuals and its level in our 
population is comparable with those reported in literature on healthy 
subjects from other population. Similar findings are seen in the 25 
healthy Swiss subjects with high phosphate intake of 1400 ± 100 mg, 
median FGF23 of 48.3 ± 4.6 RU/ml and serum phosphate of 3.90 ± 0.09 
mg/dl (Table 4).
This is the first study from Pakistan that has determined plasma 
FGF23 levels in healthy subjects. Median plasma FGF23 in apparently 
normal healthy subjects is 49.9 (IQR=33-76.1), at serum phosphate 
of 3.3 ± 3.91 mg/dl and dietary phosphate intake of 1220.3 ± 426.4 
mg. Plasma FGF23 was not different between the low and normal 
phosphate group. Increased FePO4 is seen in the subjects, most likely to 
be due to high dietary phosphate intake.
Significant association was not found which may be due to 
small sample size. In addition, parathyroid hormone levels were not 
measured which has positive effect on urinary phosphate excretion. 
High PTH is a frequent finding in our population due to prevalent 
vitamin D deficiency [10]. 
Serum phosphate homeostasis is a dynamic process and its vivo 
levels are balanced by a coordinated process including phosphate gut 
absorption, preservation and efflux of bone and cellular phosphate 
along with the urinary excretion from the kidneys. It is done mainly 
by kidneys which maintain serum phosphate levels by controlling its 
excretion stimulated by changes in dietary pattern of phosphate. Most 
of the phosphate load is cleared by kidneys and it is considered a vital 
organ in maintaining the phosphate homeostasis.
Literature showed that disorders of phosphate metabolism are 
risk factors for cardiovascular complications and these findings lead 
to phosphate intake restrictions as part of treatment for the enhanced 
prognosis in patients with cardiovascular diseases as increased 
phosphate intake was the main causative factor in the studied 
population. The novel mediators of phosphate metabolism i.e., FGF23 
and klotho are linked to dietary phosphate intake and are integral 
markers of phosphate overload and its bad prognosis.
Furthermore, serum phosphate was weakly associated with FGF-
23 and it was also not statistically significant in our healthy volunteers 
whereas a significant correlation was seen with FePO4 and serum 
creatinine. Westerberg et al. also showed negative linear correlations 
between FGF23 and phosphate and between FGF23 and TmP/GFR was 
borderline significant in their small sample done on healthy donors 
before nephrectomy [11]. Recent literature showed special focus on 
FGF23 and its association with phosphate homeostasis and vitamin D 
abnormalities in patients with chronic renal failure. 
Serum Phosphate p-value
<2.5 (n=6) 2.5 to 4.5 (n=73)
FGF23 (RU/ml) 52.3
(IQR = 31.8 to 75.3)
48.6
(IQR= 32.3 to 81.6)
0.988
TmP/GFR
(mg/dl)
2.1 ± 0.22 3.1 ± 0.47 0.000***
Dietary Phosphate 
Intake (mg)
1174 ± 519 1219 ± 416 0.563
FePO4 (%) 7.9 ± 4.1 9.1 ± 4.7 0.468
Serum Creatinine
(mg/dl)
0.6 ± 0.2 0.8 ± 0.2 0.033*
*p-value<0.05
***p-value<0.001
Groups were compared by using Mann-Whitney U test. There is significant 
difference between TmP/GFR and serum creatinine between the two groups. 
FGF-23, Fibroblast growth factor 23; TmP/GFR, Tubular maximum re-absorption 
of phosphorus per unit of GFR; PO4, Phosphate; FePO4, fractional excretion of 
Phosphate.
Table 2: Indices of Renal Handling, Dietary Phosphate Intake and FGF-23 In 
Subjects With Low and Normal Serum Phosphate Levels (n=79).
Independent Variables
(X)
Dependent Variable (Y)                 R2
FGF23
 β P   
Gender -0.11 0.038
0.598 i.e., 
59.8%
BMI -0.01 0.157
Dietary Phosphate Intake 0.00086 0.698
S. Phosphate -2.18 0.245
S. Creatinine -1.44 0.009
TmP/GFR 2.62 0.084
FePO4 0.12 0.019
The regression coefficient β and P values for potential determinants (X) i.e. 
Gender. S. Creatinine and FePO4 of FGF23 was positively associated and changes 
in response to FGF23 levels in healthy individuals. It was calculated by multiple 
regression analysis in 80 subjects and R2 showing good regression of FGF23 i.e. 
59.8%.  FePO4, fractional excretion of phosphate. Significant P values are shown 
in bold.
Table 3: Correlates between FGF23 and indices of renal handling.
 Median FGF23
 Quartile 1
32.6
Quartile 2
49.3
Quartile 3
73.9
Age 26 30 36
S. PO4 3.5 3 2.1
S. CR 0.8 0.5 0.9
FEPO4 6.87 8.79 16.58
TmP/GFR 3.26 2.74 1.75
TPO 1588.24 1305.87 1588.24
Table 4:  Distribution of dietary phosphate and indices of renal handling with 
median FGF23 quartiles.
Study Year Author Study Subjects Population FGF-23 levels Other Parameters included
2003 Jonsson et al. [22] 141 adult Caucasians 55 ± 50 RU/ml Normal Phosphate
2003 Weber et al. [4] 42 adults Caucasians Median 13 RU/ml (5 to 210) Ca2+ 9.5 ± 0.1 mg/dl, PO4 3.7 ± 0.1mg/dl, median creatinine 0.9 (0.6-
1.3) mg/dl, median iPTH 34 (11-77).
2005 Ferrari et al. [24] 29 healthy males Swiss 48.3 ± 4.6 RU/ml Serum Phosphate  3.90 ± 0.09 mg/dl, PO4 intake 1400 ± 100 mg, TmP/
GFR  3.57 ± 0.09 mg/dl, PTH  26 ± 2.1 pg/ml, 1, 25 OH vit D  37.5 ± 
1.0 pg/ml.
2009 Laroche et al.[12] 15 adults French  39.1 ± 16.4 RU/ml Serum phosphate 3.2 ± 0.5 mg/dl, PTH  21 ± 8 pg/ml, Ca2+ 9.7 ±  0.8 
mg/dl
2015 Abbas et al. 80 healthy adults Pakistani Median 49.9 RU/ml (33-76.1) Serum phosphate 3.35 ±  3.91 mg/dl, dietary Phosphate 1220 ± 426 
mg, TmP/GFR 3.04 ± 0.57 mg/dl, FePO4 7.0 ± 4.7%
Table 5: Various studies reporting FGF-23 levels in healthy controls.
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4. Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in 
normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234.
5. Iqbal R, Haroon MA, Dar FJ, Bilgirami M, Bano G, et al. (2014) Validation of a 
food frequency questionnaire for assessing macronutrient and calcium intake in 
adult Pakistani population. J Coll Physicians Surg Pak 24: 224-227.
6. Kassam-Khamis T, Judd PA, Thomas JE (2000) Frequency of consumption 
and nutrient composition of composite dishes commonly consumed in the UK 
by South Asian Muslims originating from Bangladesh, Pakistan and East Africa 
(Ismailis). J Hum Nutr Diet 13: 185-196. 
7. Fukumoto S, Yamashita T (2003) Fibroblast growth factor 23 in oncogenic 
osteomalacia and X-linked hypophosphatemia. N Engl J Med 349: 505-506.
8. Laroche M, Boyer JF, Jahafar H, Allard J, Tack I (2009) Normal FGF23 levels in 
adult idiopathic phosphate diabetes. Calcif Tissue Int 84: 112-117.
9. Bagga A, Bajpai A, Menon S (2005) Approach to renal tubular disorders. Indian 
J Pediatr 72: 771-776.
10. Mansoor S, Habib A, Ghani F, Fatmi Z, Badruddin S, et al. (2010) Prevalence 
and significance of vitamin D deficiency and insufficiency among apparently 
healthy adults. Clin Biochem 43: 1431-1435.
11. Westerberg PA, Ljunggren O, Larsson TE, Wadström J, Linde T (2010) 
Fibroblast growth factor-23 and mineral metabolism after unilateral 
nephrectomy. Nephrol Dial Transplant 25: 4068-4071.
12. Harinarayan CV, Ramalakshmi T, Prasad UV, Sudhakar D, Srinivasarao PV, 
et al. (2007) High prevalence of low dietary calcium, high phytate consumption, 
and vitamin D deficiency in healthy south Indians. Am J Clin Nutr 85: 1062-1067.
13. Witteveen JE, van Lierop AH, Papapoulos SE, Hamdy NA (2012) 
Increased circulating levels of FGF23: An adaptive response in primary 
hyperparathyroidism? Eur J Endocrinol 166: 55-60.
Our study has some limitations, first of all, small sample size of the 
study, which limits the applicability of our findings to other studies. 
Secondly, we have not assessed the vitamin D, serum calcium levels and 
PTH in this study which is another well described biologic modifiers of 
FGF23 i.e., it inhibits 1α-hydroxylation of leading to low levels of 1,25 
(OH)2 D. These findings are significant in our population where there is 
a high risk of bone diseases due to increased high incidence of vitamin 
D deficiency [12,13] and use of a diet which is rich in phosphate 
and low in calcium. Moreover, Recently FGF23 is also connected to 
hypertension, obesity and metabolic syndrome which are prevalent in 
our population. If such data can be authenticated in our population 
settings, this would represent a key paradigm move that changed 
FGF23 from biomarker to mechanism of disease, and raises the option 
of FGF23 being a primary target for intervention.
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